Spyre Therapeutics GAAP EPS of -$0.74 misses by $0.05
Source: SeekingAlpha
2026-05-05 08:07:36 ET
More on Spyre Therapeutics
- Spyre Therapeutics: Strong SPY001 Data Set Up A Catalyst-Rich 2026
- Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis - Slideshow
- Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Transcript
- Spyre Therapeutics prices upsized $403M stock deal; gross proceeds exceed initial $300M goal
- Spyre Therapeutics launches $300M public stock offering
Read the full article on Seeking Alpha
For further details see:
Spyre Therapeutics GAAP EPS of -$0.74 misses by $0.05
Spyre Therapeutics Inc.
NASDAQ: SYRE
SYRE Trading
4.49% G/L:
$72.20 Last:
891,993 Volume:
$70.325 Open:
SYRE Latest News
SYRE Stock Data
$2,603,991,883
65,619,664
1.61%
44
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
